Zinc Supplementation Reduces Insulin Resistance in PCOS Through mTOR Pathway
New rat study shows zinc methionine at 75mg/kg reduces insulin resistance and mTOR gene expression in polycystic ovarian syndrome.
Summary
Researchers studied zinc's effects on polycystic ovarian syndrome (PCOS) in rats, finding that zinc methionine supplementation significantly reduced insulin resistance and inflammation. The study tested different zinc doses over 6 weeks, with 75mg/kg showing optimal benefits. Zinc supplementation decreased fasting glucose, insulin levels, and expression of mTOR pathway genes (Raptor and Rictor) that drive PCOS symptoms. This suggests zinc could be a valuable therapeutic approach for managing PCOS and its metabolic complications.
Detailed Summary
Polycystic ovarian syndrome (PCOS) affects millions of women worldwide and is closely linked to insulin resistance and metabolic dysfunction. This research investigated whether zinc supplementation could improve PCOS symptoms by targeting the mTOR signaling pathway, which regulates cell growth and metabolism.
Researchers induced PCOS in rats using estradiol valerate, then treated groups with different doses of zinc methionine (25, 75, or 175 mg/kg daily) for six weeks. They measured fasting glucose, insulin levels, insulin resistance indices, and expression of mTOR-related genes Raptor and Rictor.
PCOS induction dramatically increased fasting glucose, insulin, insulin resistance, and mTOR gene expression. However, zinc supplementation, particularly at 75 mg/kg, significantly reversed these effects. The optimal dose reduced insulin resistance and downregulated the problematic mTOR signaling that contributes to PCOS pathology.
These findings suggest zinc supplementation could offer a natural therapeutic approach for managing PCOS and its metabolic complications. The mTOR pathway is central to aging and longevity research, making this connection particularly relevant for healthspan optimization. However, this was an animal study using induced PCOS, so human trials are needed to confirm these benefits and establish optimal dosing protocols for women with PCOS.
Key Findings
- Zinc methionine at 75mg/kg optimally reduced insulin resistance in PCOS rats
- Zinc supplementation decreased mTOR pathway gene expression (Raptor and Rictor)
- PCOS-induced increases in fasting glucose and insulin were reversed by zinc
- Organic zinc showed dose-dependent effects on metabolic parameters
Methodology
Researchers used estradiol valerate to induce PCOS in rats, then administered three different doses of zinc methionine daily for 6 weeks. They measured metabolic markers and gene expression levels in both control and PCOS groups.
Study Limitations
This study was conducted in rats with chemically-induced PCOS, so results may not directly translate to humans. The summary is based on the abstract only, limiting detailed methodology assessment. Human trials are needed to confirm efficacy and safety.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.